| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 05/19/2022 | 45.07% | Piper Sandler | $81 → $44 | Maintains | Overweight |
| 05/18/2022 | 71.45% | Guggenheim | $70 → $52 | Maintains | Buy |
| 05/18/2022 | 51.67% | Jefferies | $78 → $46 | Maintains | Buy |
| 05/18/2022 | 31.88% | Raymond James | $60 → $40 | Maintains | Outperform |
| 05/18/2022 | 15.4% | Morgan Stanley | $55 → $35 | Maintains | Equal-Weight |
| 05/18/2022 | 48.37% | Baird | $68 → $45 | Maintains | Outperform |
| 05/18/2022 | 48.37% | Needham | $70 → $45 | Maintains | Buy |
| 05/18/2022 | 120.9% | SVB Leerink | $72 → $67 | Maintains | Outperform |
| 04/07/2022 | 130.79% | Guggenheim | → $70 | Initiates Coverage On | → Buy |
| 04/04/2022 | 81.34% | B of A Securities | → $55 | Initiates Coverage On | → Neutral |
| 03/23/2022 | 81.34% | Morgan Stanley | $62 → $55 | Maintains | Equal-Weight |
| 02/11/2022 | 143.98% | Goldman Sachs | → $74 | Initiates Coverage On | → Buy |
| 02/09/2022 | 97.82% | Raymond James | $80 → $60 | Maintains | Outperform |
| 02/09/2022 | 130.79% | Needham | $90 → $70 | Maintains | Buy |
| 12/17/2021 | 91.23% | Morgan Stanley | $72 → $58 | Maintains | Equal-Weight |
| 12/14/2021 | 97.82% | JP Morgan | $70 → $60 | Downgrades | Neutral → Underweight |
| 12/02/2021 | 157.17% | Jefferies | → $78 | Initiates Coverage On | → Buy |
| 11/17/2021 | 176.95% | Baird | → $84 | Initiates Coverage On | → Outperform |
| 11/10/2021 | 163.77% | Raymond James | $62 → $80 | Maintains | Outperform |
| 11/10/2021 | 196.74% | Needham | $62 → $90 | Maintains | Buy |
| 11/10/2021 | 137.39% | SVB Leerink | $65 → $72 | Maintains | Outperform |
| 08/31/2021 | 134.09% | Morgan Stanley | $52 → $71 | Maintains | Equal-Weight |
| 08/26/2021 | 130.79% | JP Morgan | → $70 | Downgrades | Overweight → Neutral |
| 08/11/2021 | 104.42% | Raymond James | $60 → $62 | Maintains | Outperform |
| 07/19/2021 | 71.45% | Morgan Stanley | → $52 | Initiates Coverage On | → Equal-Weight |
| 07/19/2021 | 97.82% | Raymond James | → $60 | Initiates Coverage On | → Outperform |
| 07/19/2021 | 104.42% | Needham | → $62 | Initiates Coverage On | → Buy |
| 07/19/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/19/2021 | 111.01% | Canaccord Genuity | → $64 | Initiates Coverage On | → Buy |
| 07/19/2021 | 114.31% | SVB Leerink | → $65 | Initiates Coverage On | → Outperform |
| 07/19/2021 | 124.2% | Piper Sandler | → $68 | Initiates Coverage On | → Overweight |
| 07/19/2021 | 18.69% | Goldman Sachs | → $36 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 97.82% | JP Morgan | → $60 | Initiates Coverage On | → Overweight |
Doximity Questions & Answers
The latest price target for Doximity (NYSE: DOCS) was reported by Guggenheim on May 18, 2022. The analyst firm set a price target for $52.00 expecting DOCS to rise to within 12 months (a possible 71.45% upside). 32 analyst firms have reported ratings in the last year.
The latest analyst rating for Doximity (NYSE: DOCS) was provided by Guggenheim, and Doximity maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Doximity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Doximity was filed on May 18, 2022 so you should expect the next rating to be made available sometime around May 18, 2023.
While ratings are subjective and will change, the latest Doximity (DOCS) rating was a maintained with a price target of $70.00 to $52.00. The current price Doximity (DOCS) is trading at is $30.33, which is out of the analyst's predicted range.